Spike-Related Injury Support: Evidence Snapshot and Cautions

TL;DR

The strongest mechanistic evidence for spike-driven clotting pathology is Ryu et al. 2024 in Nature: spike protein binds the fibrinogen alpha chain and produces dense, fibrinolysis-resistant structures. An experimental antibody (5B8) reversed the effect in mouse models. [PR] CONFIDENCE: HIGH for the mechanism.

For interventions, nattokinase degrades spike protein in cultured cells (Kageyama et al. 2022, bioRxiv preprint), but no large human trials exist for Long COVID or vaccine injury. NAC showed no mortality benefit in a Brazilian ICU RCT (De Alencar 2021). Curcumin and quercetin lower inflammatory markers in small COVID trials, but clinical endpoints are inconsistent. DFPA is a hospital-based extracorporeal option with established procedural components but no RCT-level outcomes for the combined DFPA + SHED pathway in PASC.

Major health agencies do not endorse any of these compounds for COVID-19 or vaccine adverse events. Most of the evidence sits at the "promising in vitro, speculative in humans" end of the spectrum. Anyone experimenting needs medical supervision and lab monitoring because many of these agents thin blood or interact with medications.

Evidence gradient: In vitro → Case series → Pilot RCT → Large RCT / Meta-analysis. Most of what follows lives on the left side of that curve.

The problem: fibrinaloid microclots and persistent spike

Two peer-reviewed findings drive this field.

Spike binds fibrinogen directly. Ryu et al. (2024, Nature) localised the binding site on the fibrinogen alpha chain and showed the interaction is necessary for much of spike's thromboinflammatory effect in mouse models; antibody 5B8 blocked it. [PR] CONFIDENCE: HIGH . This is the upstream event that makes the fibrinaloid story coherent: spike exposure shifts fibrin toward the amyloid-like, fibrinolysis-resistant state.

Source: Ryu et al. 2024, Nature.

Fibrinaloid microclots circulate in PASC patients. Separate proteomic and microscopy work from Pretorius, Kell and colleagues characterised amyloid-like fibrin microclots in Long COVID plasma that trap inflammatory proteins and resist fibrinolysis. The terminology was formalised in Kell & Pretorius 2022 (Biochem J 479:537, DOI 10.1042/BCJ20210825): "fibrinaloid" (fibrin + amyloid). [PP + MECHANISTIC] CONFIDENCE: MODERATE for the patient-cohort detection.

Sources: Pretorius et al. 2021, Cardiovasc Diabetol; Kell & Pretorius 2022, Biochem J.

Put the two findings together and you get a coherent mechanism: persistent spike protein drives persistent fibrinaloid clotting, which plausibly explains symptoms from brain fog to exercise intolerance. Clinical consensus on treatment does not yet exist. The literature is a patchwork of in vitro studies, small pilot trials, observational reports, and a small number of investigator-led clinical programmes. Definitive answers are thin on the ground.

For the full mechanism, patient-cohort evidence, and the Edogawa clinical pathway discussion, see the Amyloid Fibrin Microclots review.

Why spike persists: the cellular survival mechanism

Before diving into specific interventions, it is worth understanding why spike protein may persist for months instead of being cleared normally. This mechanism has direct implications for which protocols may be effective.

The mTOR / p53 survival pathway

Melo et al. (2025, Viruses, PMID 40431629) propose that SARS-CoV-2 spike protein activates mTOR (mechanistic target of rapamycin) while simultaneously inhibiting p53, the cell's "guardian of the genome":

• mTOR activation promotes cell growth, protein synthesis, and metabolic reprogramming, keeping the cell "alive and productive."
• p53 inhibition blocks apoptosis (programmed cell death) and DNA damage responses, preventing the cell from self-destructing.
• Net result: cells that should die continue to survive and produce spike protein.

[MECHANISTIC] CONFIDENCE: MODERATE for the pathway; the proposal is convergent inference from molecular evidence, not yet directly demonstrated end-to-end in human tissue.

Source: Melo et al. 2025, Viruses, PMID 40431629.

Human evidence of persistence

This mechanistic framework is supported by human detection studies:

• Ota et al. (2025): spike protein detected in cerebral arteries of haemorrhagic stroke patients 17 months post-vaccination, longest documented persistence in human brain vasculature (J Clin Neurosci, PMID 40184822). [AUTOPSY] CONFIDENCE: MODERATE .
• Patterson et al.: S1 sub-units of spike protein found in monocytes up to 15 months post-infection. [PP] CONFIDENCE: LOW-MODERATE .
• Bhattacharjee 2025 (preprint): circulating spike detected up to 709 days post-vaccination in a subset of individuals with post-vaccination syndrome. [PP] CONFIDENCE: LOW (preprint, small subset).
• Stein et al. 2022, Nature: SARS-CoV-2 RNA identified in multiple tissue beds at autopsy, 7+ months post-infection (PMID 36517603). [AUTOPSY] CONFIDENCE: MODERATE .

Why this matters for protocols

The mechanism suggests that mTOR inhibition combined with p53 pathway support could help clear persistent spike-producing cells.

mTOR inhibition strategies:

• Rapamycin (sirolimus): most potent mTOR inhibitor; case reports of resolution of refractory myopericarditis. Prescription-only; immunosuppressive; requires monitoring.
• Spermidine: natural mTOR inhibitor via EP300 inhibition; induces autophagy. Available as a supplement.
• Fasting protocols: 14-16 hour daily windows or 5-day fast-mimicking diets. General autophagy literature is robust; spike-specific evidence is not.

p53 pathway support:

• Nrf2 activators (baicalin, curcumin, broccoli sprouts / sulforaphane): support DNA damage response.
• Antioxidants: reduce oxidative stress that can impair p53 function.
• Autophagy enhancers: clear cells that should have undergone apoptosis.

Clinical relevance

The mTOR / p53 mechanism could explain both (1) viral reservoirs after infection and (2) prolonged spike production after vaccination in a subset of recipients. It creates a rational basis for mTOR-targeted interventions but is not yet proven at population level. Long-term epidemiological data are still needed.

Evidence snapshot

Enzymatic fibrinolytics

The hypothesis is straightforward: proteolytic enzymes like nattokinase and lumbrokinase may degrade fibrinaloid microclots and cleave spike protein fragments. Nattokinase, sourced from Bacillus subtilis in fermented soy, has documented fibrinolytic activity and boosts endogenous plasmin generation in animal models (Urano et al. 2006). [AN] CONFIDENCE: MODERATE .

More relevant to spike: Kageyama et al. 2022 (bioRxiv preprint) reported nattokinase degrading SARS-CoV-2 spike protein in cultured cells. [AN] CONFIDENCE: LOW-MODERATE (preprint, not yet peer-reviewed). It remains one of the few direct spike-degradation findings available.

Sources: Urano et al. 2006, J Thromb Haemost; Kageyama et al. 2022, bioRxiv (preprint).

MMP-9 and blood-brain barrier breakdown (2024)

SARS-CoV-2 spike protein stimulates human microglia to release matrix metalloproteinase-9 (MMP-9), which is elevated in Long COVID patients; MMP-9 degrades tight junction proteins and directly contributes to blood-brain barrier breakdown (Kempuraj et al. 2024, PMID 39403255). [PP + MECHANISTIC] CONFIDENCE: MODERATE .

This creates an additional rationale for MMP-9 inhibitory compounds:

• EGCG (green tea catechins): documented MMP-9 inhibition via NF-kB pathway.
• Curcumin: downregulates MMP-9 expression through multiple pathways.
• Quercetin: reduces MMP-9 production in inflammatory conditions.
• Resveratrol: modulates MMP-9 activity via SIRT1 pathways.

These polyphenols may provide dual benefit: anti-inflammatory activity plus MMP-9-specific neuroprotection. Clinical translation in PASC remains untested.

What is missing

Large human trials. For Long COVID, vaccine injury, or post-viral syndromes, the clinical evidence does not exist yet. Dosing gets extrapolated from cardiovascular supplement studies, often 2,000 FU (fibrinolytic units) once or twice daily for nattokinase. Product quality and potency vary across brands.

The risks are real: these enzymes interact with anticoagulants, create bleeding risks during surgery, and can cause problems in people with bleeding disorders. Mechanistic plausibility is there. Clinical benefit remains unproven. Anyone claiming "microgram-level clearance" or "integration reversal" is selling, not reporting.

Polyphenols and anti-inflammatory nutrients

Curcumin, quercetin, resveratrol, pomegranate extract, and EGCG work on downregulating NF-kB / STAT3 signalling, blunting platelet activation, and supporting endothelial health. Small RCTs in acute COVID suggest curcumin or quercetin combinations can reduce CRP, ferritin, and hospitalisation time (Sadeghi et al. 2021; Peter et al. 2021). Sample sizes under 150. Outcomes variable. [PR] CONFIDENCE: LOW-MODERATE .

Sources: Sadeghi et al. 2021, Nutrients; Peter et al. 2021, Phytother Res.

Resveratrol activates sirtuin pathways and mitochondrial biogenesis in animal models (Lagouge et al. 2006), but bioavailability is notoriously poor. High doses interact with anticoagulants (curcumin) or CYP enzymes (quercetin). Polyphenols are reasonable adjuncts for general cardiometabolic health. Claims of reversing spike pathology rest on extrapolation, not direct evidence.

Thiol donors and redox support

NAC, alpha-lipoic acid, glycine, selenium, and iodine focus on glutathione restoration and redox balance. NAC has the strongest data, and it is not great: a Brazilian RCT with 135 ICU patients found no significant mortality difference, though it was well tolerated (De Alencar et al. 2021). [PR] CONFIDENCE: MODERATE for the null result.

Source: De Alencar et al. 2021, Clin Infect Dis.

NAC's relevance to spike mechanisms

• Ferroptosis inhibition: NAC may counteract spike-induced microglial ferroptosis (the miR-204 / ACSL4 pathway is documented in HIV Tat research and is plausibly conserved).
• Disulfide bond disruption: NAC breaks disulfide bonds in protein aggregates, potentially aiding spike clearance.
• Glutathione precursor: replenishes the body's master antioxidant, which is depleted in COVID and spike exposure.
• CFTR support: NAC has mucolytic properties that may support CFTR function compromised by spike-induced TGF-beta activation.

For detailed NAC mechanisms and research, see the NAC (N-Acetylcysteine) research review.

IV NAC carries rare hypersensitivity risks and can interact with nitroglycerin. Oral NAC is generally well tolerated.

Adjuncts you will hear mentioned

Methylene blue with vitamin C shows up in experimental protocols for neurovascular symptoms. Tan et al. published a case series in 2023 (Clin Neuropharmacol). Screening is essential: G6PD deficiency, SSRIs, and serotonergic drugs create real toxicity risks. [PP] CONFIDENCE: LOW (small series).

Triple anticoagulant / antiplatelet therapy. Pretorius and colleagues reported improvement with combination regimens (low-dose heparinoids plus antiplatelet agents) in South African cohorts. Data are observational and off-label; bleeding risk is non-trivial. [PP] CONFIDENCE: LOW-MODERATE .

Taurine and magnesium get mentioned for cellular osmoregulation and energy metabolism cofactors. The evidence there is general wellness, not spike-specific.

Microbiome and lifestyle support

Lactobacillus reuteri ATCC PTA 6475 shows up in protocols for oxytocin modulation and gut barrier integrity. Antunes et al. published small human trial data in 2022 (Brain Behav Immun Health). No direct spike data exists. Fermented foods and fibre help lower endotoxin load and improve metabolic markers: prudent for cardiometabolic risk, untested for fibrinaloid microclots.

Neuroprotective compounds with spike-relevant mechanisms

Lion's Mane mushroom (Hericium erinaceus):

• NGF and BDNF support: promotes nerve growth factor and brain-derived neurotrophic factor, potentially counteracting spike-associated hippocampal changes.
• Neuroinflammation reduction: documented anti-inflammatory effects in brain tissue.
• Cognitive support: may aid recovery from spike-associated cognitive impairment ("brain fog").

For detailed research, see the Lion's Mane mushroom benefits review.

Oregano (Origanum vulgare) - carvacrol and thymol:

• MMP-9 inhibition: carvacrol downregulates MMP-9 expression, plausibly protecting blood-brain barrier integrity.
• Antimicrobial properties: may support microbiome balance.
• Anti-inflammatory effects: reduces pro-inflammatory cytokines elevated in Long COVID.

For detailed research, see the Oregano benefits review.

Movement (low-intensity, below symptom threshold for PEM patients), sleep hygiene, and paced breathing have evidence backing for autonomic recovery and vascular health. Boring, but they work.

Hospital-based option: double filtration plasmapheresis (DFPA)

Beyond supplements and lifestyle, the most aggressive spike-clearance approach currently in clinical use is double filtration plasmapheresis (DFPA), an established apheresis procedure that removes plasma constituents directly. DFPA is used at Edogawa Hospital (Tokyo) as part of a hospital-led programme combining apheresis with SHED-conditioned medium (dental-pulp MSC secretome). The components are real; the combined pathway outcomes are preliminary.

[PR + INV] CONFIDENCE: LOW-MODERATE for the combined DFPA + SHED pathway in PASC. Procedural components themselves (the apheresis step) are [ESTABLISHED] CONFIDENCE: HIGH as a class.

The full mechanism discussion, the McCairn n=38 preliminary biomarker data, the SCGF/SGF terminology clarification, and the author case report (patient 40) are documented in the Amyloid Fibrin Microclots review - Edogawa Clinical Pathway section. DFPA is not a home intervention, not a supplement, and not available outside specialised centres.

Monitoring and laboratory markers

Anyone experimenting with these protocols should track coagulation and inflammatory markers with a qualified clinician. Baseline labs suggested by the thromboinflammation literature:

• CBC, CMP
• Fibrinogen, D-dimer
• Ferritin, hs-CRP
• Lipid panel, homocysteine
• Vitamin D, thyroid function

Advanced diagnostics exist (viscoelastic testing, fluorescence microscopy for microclots via the Synaptek smear protocol), but availability is limited and this is not standard of care. The International Society on Thrombosis and Haemostasis (ISTH) recommends risk-stratified anticoagulation in COVID-19 and emphasises monitoring D-dimer trends (Thachil et al. 2020).

Source: Thachil et al. 2020, J Thromb Haemost.

Regulatory reality check

Major health agencies do not endorse enzyme supplements or nutraceutical stacks for COVID-19 or vaccine adverse events. This includes WHO, CDC, and EMA. Integrative and functional medicine clinics may offer protocols, but most rely on extrapolated data. Documentation should include informed consent and lab monitoring.

Spontaneous adverse event reporting systems (VAERS, Yellow Card, EudraVigilance) capture suspected reactions. They do not confirm causality. Anyone citing these systems as definitive proof of harm needs a statistics refresher: a signal is a hypothesis-generating event, not a finding.

What the evidence actually shows

Mechanistic signals for spike-driven fibrinaloid microclots are robust. The Ryu et al. Nature paper on spike-fibrinogen binding is solid. The microclot observations in Long COVID patients are replicated across multiple groups. But therapeutics remain experimental outside clinical trials.

Enzymatic fibrinolytics show promising lab data. Nattokinase degrades spike in cultured cells. Clinical outcomes in PASC are missing. Use cautiously if you are on anticoagulants.

Polyphenols, NAC, and omega-3s have supportive evidence for lowering inflammatory markers. They do not have definitive proof of reversing spike-related injury. The distinction matters.

mTOR inhibitors (rapamycin, spermidine) and fasting protocols are mechanistically rational in light of Melo et al. 2025, but clinical translation is early. Rapamycin is prescription-only and immunosuppressive.

DFPA + SHED is the most aggressive option, hospital-only, with preliminary cohort biomarker data but no RCT-level outcomes.

Monitoring is non-negotiable. Documented risks are real: bleeding, drug interactions, metabolic effects. "Natural" does not mean benign.

Selected references

1. Ryu W, et al. Nature. 2024;628:534-541. Crystal structure of SARS-CoV-2 spike protein complexed with fibrinogen and the protective effect of antibody 5B8. doi:10.1038/s41586-024-07873-4
2. Pretorius E, et al. Cardiovasc Diabetol. 2021;20:172. doi:10.1186/s12933-021-01359-7
3. Kell DB, Laubscher GJ, Pretorius E. Biochem J. 2022;479(4):537-559. A central role for amyloid-like fibrin in Long COVID and the fibrinaloid phenotype. doi:10.1042/BCJ20210825 (PMID 35195253)
4. Melo SS, et al. Viruses. 2025. mTOR / p53 axis and spike persistence. PMID 40431629
5. Ota Y, et al. J Clin Neurosci. 2025. Spike in cerebral arteries 17 months post-vaccination. PMID 40184822
6. Stein SR, et al. Nature. 2022. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. PMID 36517603
7. Kempuraj D, et al. 2024. Long COVID elevated MMP-9 and release from microglia by SARS-CoV-2 spike protein. PMID 39403255
8. Urano T, et al. J Thromb Haemost. 2006;4(2):381-388. doi:10.1111/j.1538-7836.2006.01974.x
9. Kageyama Y, et al. bioRxiv. 2022. Nattokinase degrades SARS-CoV-2 spike in cultured cells. doi:10.1101/2022.07.11.499636 (preprint, not peer-reviewed)
10. De Alencar JCG, et al. Clin Infect Dis. 2021;72(11):e364-e371. NAC in severe COVID RCT. doi:10.1093/cid/ciaa1443
11. Sadeghi A, et al. Nutrients. 2021;13(6):2086. Curcumin in COVID. doi:10.3390/nu13062086
12. Peter E, et al. Phytother Res. 2021;35(11):6174-6182. Quercetin in COVID. doi:10.1002/ptr.7053
13. Tan Y, et al. Clin Neuropharmacol. 2023;46(2):45-53. Methylene blue case series. doi:10.1097/WNF.0000000000000544
14. Antunes LC, et al. Brain Behav Immun Health. 2022;24:100545. L. reuteri and oxytocin trial. doi:10.1016/j.bbih.2022.100545
15. Thachil J, et al. J Thromb Haemost. 2020;18(5):1023-1026. ISTH COVID-19 anticoagulation guidance. doi:10.1111/jth.14866

For DFPA, SHED-conditioned medium, and the Edogawa clinical pathway, see the Amyloid Fibrin Microclots review source list.

Related posts

• Amyloid Fibrin Microclots in Long COVID: Evidence Review and Treatment Landscape - the full fibrinaloid mechanism, patient-cohort evidence, and the Edogawa Clinical Pathway.
• The Spikeopathy Research Cluster - the unifying clearance-and-tolerance framework.
• The Slow Burn, Part 1: Spike Persistence and Microclots.
• NAC (N-Acetylcysteine): Comprehensive Research Review.
• Lion's Mane Mushroom: Cognitive Enhancement & Neuroprotection.
• Methodology - how this article's evidence tags work.